Wegovy is a higher dose version of the diabetes drug semaglutide. It was approved by the USFDA in June 2021 for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment or in patients with a BMI of 30 kg/m2 or greater.
from Times of India https://ift.tt/0TsKjHJ
from Times of India https://ift.tt/0TsKjHJ